ArticleBritish journal of cancer2023

Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.

J-S Frenel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.